Thank you to our speakers, sponsors, and delegates who joined us in December 2024 for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com.
With the applications of LNPs rapidly expanding beyond vaccines, as well as beyond the liver, it was of utmost importance to predict and minimize adverse reactions to guarantee patient safety in the clinic, especially following a clinical hold on Verve Therapeutics ’ gene therapy earlier this year, due to safety concerns surrounding the LNP delivery system.
In December, the 3rd LNP Immunogenicity & Toxicity Summit allowed attendees to join forces with industry experts striving to transform non-clinical and clinical safety risk assessments for LNPs and testing strategy to confidently measure, predict and monitor lipid nanoparticles safety profiles to progress and support development of safe and regulatory compliant vaccines, gene and cell therapies.
Attendees learnt from and collaborated with experts from Pfizer, AstraZeneca, Moderna, BioNTech and Beam Therapeutics as they sought to
- Reinvent prediction by advancing in vitro tools and screens
- Overcome PEG immunogenicity by measuring anti-PEG responses and exploring PEG alternatives
- Measure tolerability to ionizable lipids to optimize LNP design
- Uncover and understand mechanisms of toxicity and immune characterization
- Determine optimal delivery strategy to mitigate safety risk
This specialised community of experts across bioanalytics, pharmacology, translation, toxicology, safety, and delivery met at the only event dedicated to assessing and measuring LNP safety risk to drive development and delivery of safer LNP-delivered therapeutics.
Companies That Attended In December:
World-Class Speakers Included:
Bin Wu,
Founder & President, Cytodigm
"From what I know, every company involved in gene and cell therapies is currently using or has plans to use the LNP platform to deliver their therapeutic payloads. LNPs usually have inherent immunogenicity and toxicity. Therefore, it is crucial to address these issues in order to pave the way for the application of these new therapies to patients. This conference provides a platform for the industry to discuss latest advancements in the relevant subjects".
"LNP's stand to be a critical platform to deliver critical therapeutics to address unmet medical needs and understanding undesired immune responses is critical to ensure safe and effective treatments. This meeting provides the opportunity to share information across industry to enable better learning, understanding, and ultimately delivery of effective medicines".
Jason Pennucci,
Director, Bioanalytical Sciences, Moderna
20+
Industry & Academic Expert Presenters
3
Jam-Packed Days of Exclusive Content
3
Deep-Dive & Collaborative Workshops
What Previous Attendees of the LNP Series Had To Say:
"I really value the ability to communicate with scientists in the field; seeing emerging techniques for analytical characterization and development." - Analytical Research Scientist
"Very relevant presentations and interesting mix of speakers from many of the key players in LNP/mRNA analytics. Very good audience which led to many opportunities for discussions and follow up." - Physicist
"I enjoyed seeing the most advanced and relevant information, as well as communication and networking with the best professionals in the area of LNP characterization and analytical development." - Associate Director
"I enjoyed all of the presentations. The conference was very well organized and ran smoothly." - Principal Research Associate
"Well attended, engaged participants, good speaker lineup, current and future challenges were discussed, ample time for networking. What stood out for me was the energy and interest from all parties." - Director
